Association Between α-Tocopherol, γ-Tocopherol, Selenium, and Subsequent Prostate Cancer
Background: Selenium and α-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of γ-tocopherol, a major component of vitamin E in the U.S. diet and the second most common toco...
Saved in:
Published in | JNCI : Journal of the National Cancer Institute Vol. 92; no. 24; pp. 2018 - 2023 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Cary, NC
Oxford University Press
20.12.2000
Oxford Publishing Limited (England) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Selenium and α-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of γ-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case–control study was conducted to examine the associations of α-tocopherol, γ-tocopherol, and selenium with incident prostate cancer. Methods: In 1989, a total of 10 456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, α-tocopherol, and γ-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided. Results: The risk of prostate cancer declined, but not linearly, with increasing concentrations of α-tocopherol (odds ratio highest versus lowest fifth = 0.65; 95% confidence interval = 0.32–1.32; Ptrend = .28). For γ-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (Ptrend = .002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (Ptrend = .27). Statistically significant protective associations for high levels of selenium and α-tocopherol were observed only when γ-tocopherol concentrations were high. Conclusions: The use of combined α- and γ- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between α-tocopherol, γ-tocopherol, and selenium. |
---|---|
AbstractList | Selenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of gamma-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case-control study was conducted to examine the associations of alpha-tocopherol, gamma-tocopherol, and selenium with incident prostate cancer.
In 1989, a total of 10,456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, alpha-tocopherol, and gamma-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided.
The risk of prostate cancer declined, but not linearly, with increasing concentrations of alpha-tocopherol (odds ratio (highest versus lowest fifth) = 0.65; 95% confidence interval = 0.32--1.32; P(trend) =.28). For gamma-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (P:(trend) =.002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (P(trend) =.27). Statistically significant protective associations for high levels of selenium and alpha-tocopherol were observed only when gamma-tocopherol concentrations were high.
The use of combined alpha- and gamma- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between alpha-tocopherol, gamma-tocopherol, and selenium. Selenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of gamma-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case-control study was conducted to examine the associations of alpha-tocopherol, gamma-tocopherol, and selenium with incident prostate cancer.BACKGROUNDSelenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of gamma-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case-control study was conducted to examine the associations of alpha-tocopherol, gamma-tocopherol, and selenium with incident prostate cancer.In 1989, a total of 10,456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, alpha-tocopherol, and gamma-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided.METHODSIn 1989, a total of 10,456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, alpha-tocopherol, and gamma-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided.The risk of prostate cancer declined, but not linearly, with increasing concentrations of alpha-tocopherol (odds ratio (highest versus lowest fifth) = 0.65; 95% confidence interval = 0.32--1.32; P(trend) =.28). For gamma-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (P:(trend) =.002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (P(trend) =.27). Statistically significant protective associations for high levels of selenium and alpha-tocopherol were observed only when gamma-tocopherol concentrations were high.RESULTSThe risk of prostate cancer declined, but not linearly, with increasing concentrations of alpha-tocopherol (odds ratio (highest versus lowest fifth) = 0.65; 95% confidence interval = 0.32--1.32; P(trend) =.28). For gamma-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (P:(trend) =.002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (P(trend) =.27). Statistically significant protective associations for high levels of selenium and alpha-tocopherol were observed only when gamma-tocopherol concentrations were high.The use of combined alpha- and gamma- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between alpha-tocopherol, gamma-tocopherol, and selenium.CONCLUSIONSThe use of combined alpha- and gamma- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between alpha-tocopherol, gamma-tocopherol, and selenium. BACKGROUND: Selenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of gamma-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case-control study was conducted to examine the associations of alpha-tocopherol, gamma-tocopherol, and selenium with incident prostate cancer. METHODS: In 1989, a total of 10,456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, alpha-tocopherol, and gamma-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided. RESULTS: The risk of prostate cancer declined, but not linearly, with increasing concentrations of alpha-tocopherol (odds ratio (highest versus lowest fifth) = 0.65; 95% confidence interval = 0.32--1.32; P(trend) =.28). For gamma-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (P:(trend) =.002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (P(trend) =.27). Statistically significant protective associations for high levels of selenium and alpha-tocopherol were observed only when gamma-tocopherol concentrations were high. CONCLUSIONS: The use of combined alpha- and gamma- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between alpha-tocopherol, gamma-tocopherol, and selenium. Background: Selenium and α-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little attention has been paid to the possible role of γ-tocopherol, a major component of vitamin E in the U.S. diet and the second most common tocopherol in human serum. A nested case–control study was conducted to examine the associations of α-tocopherol, γ-tocopherol, and selenium with incident prostate cancer. Methods: In 1989, a total of 10 456 male residents of Washington County, MD, donated blood for a specimen bank. A total of 117 of 145 men who developed prostate cancer and 233 matched control subjects had toenail and plasma samples available for assays of selenium, α-tocopherol, and γ-tocopherol. The association between the micronutrient concentrations and the development of prostate cancer was assessed by conditional logistic regression analysis. All statistical tests were two-sided. Results: The risk of prostate cancer declined, but not linearly, with increasing concentrations of α-tocopherol (odds ratio highest versus lowest fifth = 0.65; 95% confidence interval = 0.32–1.32; Ptrend = .28). For γ-tocopherol, men in the highest fifth of the distribution had a fivefold reduction in the risk of developing prostate cancer than men in the lowest fifth (Ptrend = .002). The association between selenium and prostate cancer risk was in the protective direction with individuals in the top four fifths of the distribution having a reduced risk of prostate cancer compared with individuals in the bottom fifth (Ptrend = .27). Statistically significant protective associations for high levels of selenium and α-tocopherol were observed only when γ-tocopherol concentrations were high. Conclusions: The use of combined α- and γ- tocopherol supplements should be considered in upcoming prostate cancer prevention trials, given the observed interaction between α-tocopherol, γ-tocopherol, and selenium. |
Author | Alberg, Anthony J. Morris, J. Steven Comstock, George W. Burke, Alyce Huang, Han-Yao Hoffman, Sandra Norkus, Edward P. Helzlsouer, Kathy J. |
Author_xml | – sequence: 1 givenname: Kathy J. surname: Helzlsouer fullname: Helzlsouer, Kathy J. organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia – sequence: 2 givenname: Han-Yao surname: Huang fullname: Huang, Han-Yao organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia – sequence: 3 givenname: Anthony J. surname: Alberg fullname: Alberg, Anthony J. organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia – sequence: 4 givenname: Sandra surname: Hoffman fullname: Hoffman, Sandra organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia – sequence: 5 givenname: Alyce surname: Burke fullname: Burke, Alyce organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia – sequence: 6 givenname: Edward P. surname: Norkus fullname: Norkus, Edward P. organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia – sequence: 7 givenname: J. Steven surname: Morris fullname: Morris, J. Steven organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia – sequence: 8 givenname: George W. surname: Comstock fullname: Comstock, George W. organization: K. J. Helzlsouer, H.-Y. Huang, A. J. Alberg, S. Hoffman, A. Burke, G. W. Comstock, Department of Epidemiology, The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; E. P. Norkus, Our Lady of Mercy Medical Center, Bronx, NY; J. S. Morris, University of Missouri, Columbia |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=908257$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11121464$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1uEzEUhS3UiqaFNTs0AolVJ_HfjD3LEkFbtRVIKQhlYzmeO8JhYqe2R8BjVbxHnwmnCUV0gTeWpe9cn3vOIdpz3gFCLwgeE9ywydIZO2nomPIxxUQ-QSPCa1xSgqs9NMKYilJKwQ_QYYxLnE9D-VN0QAihGeQjND-J0Rurk_WueAvpO4Ar7m7La2_8-isE3x8Xd7_-ec6gB2eH1XGhXVvMhkWEmwFcKj4GH5NOUEy1MxCeof1O9xGe7-4j9On9u-vpWXn54fR8enJZGi5JKiXTnFHDmwVtq-yJsxZqYihuJdSilbhi2hjQnRBt08mubiouONRdq4XWmLIj9GY7dx18NhKTWtlooO-1Az9EJWjFuKyaDL56BC79EFz2pmhOjDJSb6CXO2hYrKBV62BXOvxUfyLLwOsdoKPRfRfysjY-cA2WtBKZmmwpk0OJAbq_g7DaVKc21amGKsrVprqsqB4pjE33vaSgbf8fXbnV2Zjgx8M3OnxTtWCiUmdf5upiPruaXdSf1ZT9BqiRrd0 |
CODEN | JNCIEQ |
CitedBy_id | crossref_primary_10_1017_S0007114516000726 crossref_primary_10_1091_mbc_e03_07_0501 crossref_primary_10_1016_j_ctrv_2009_12_008 crossref_primary_10_1158_1940_6207_CAPR_10_0343 crossref_primary_10_1186_1475_2891_7_13 crossref_primary_10_1308_003588407X179125 crossref_primary_10_1093_jnci_dji009 crossref_primary_10_1007_s13749_013_0051_5 crossref_primary_10_1158_1055_9965_378_13_3 crossref_primary_10_1196_annals_1331_056 crossref_primary_10_1016_j_jaad_2006_04_014 crossref_primary_10_1016_j_ucl_2004_03_007 crossref_primary_10_2174_0115734137279106231227044328 crossref_primary_10_4137_LPI_S5788 crossref_primary_10_1080_07315724_2013_862490 crossref_primary_10_1194_jlr_M600291_JLR200 crossref_primary_10_1016_S0098_2997_03_00028_1 crossref_primary_10_1080_01635581_2012_630552 crossref_primary_10_1038_aja_2011_142 crossref_primary_10_1002_ijc_25033 crossref_primary_10_1073_pnas_102014399 crossref_primary_10_1079_BJN20051471 crossref_primary_10_1038_sj_pcan_4500569 crossref_primary_10_1111_jhn_12146 crossref_primary_10_1016_S0090_4295_01_01190_6 crossref_primary_10_1049_nbt2_12074 crossref_primary_10_1016_j_biomaterials_2011_05_032 crossref_primary_10_1080_10942912_2015_1114951 crossref_primary_10_1158_1055_9965_EPI_06_1071 crossref_primary_10_3945_ajcn_111_033373 crossref_primary_10_1097_01_ju_0000142058_99614_ff crossref_primary_10_1016_j_ejca_2004_12_033 crossref_primary_10_1586_14737140_3_2_203 crossref_primary_10_1016_j_aninu_2020_11_010 crossref_primary_10_3389_fmars_2022_1092343 crossref_primary_10_1007_s12668_024_01431_y crossref_primary_10_1200_JCO_2005_06_190 crossref_primary_10_1158_1055_9965_EPI_06_1084 crossref_primary_10_1080_1061186X_2024_2324935 crossref_primary_10_1002_pros_10115 crossref_primary_10_1093_ije_dyv156 crossref_primary_10_3390_molecules15031762 crossref_primary_10_1158_1055_9965_EPI_05_0585 crossref_primary_10_1016_S0090_4295_02_01641_2 crossref_primary_10_1016_j_bcp_2013_07_018 crossref_primary_10_1016_j_phymed_2017_06_008 crossref_primary_10_2135_cropsci2007_11_0658 crossref_primary_10_62313_ijpbp_2024_251 crossref_primary_10_1016_j_jaad_2014_01_910 crossref_primary_10_2135_cropsci2005_07_0227 crossref_primary_10_1016_S0094_0143_02_00181_7 crossref_primary_10_1039_C6RA11821F crossref_primary_10_1158_1055_9965_EPI_13_0670 crossref_primary_10_1002_pros_21012 crossref_primary_10_4103_0022_3859_43549 crossref_primary_10_1158_1055_9965_EPI_05_0471 crossref_primary_10_1111_j_1464_410X_2004_04795_x crossref_primary_10_1038_s41598_020_80433_8 crossref_primary_10_1002_mnfr_200800103 crossref_primary_10_1049_nbt2_12025 crossref_primary_10_1517_13543784_13_12_1541 crossref_primary_10_1111_j_1464_410X_2010_09344_x crossref_primary_10_1017_S0954422407202938 crossref_primary_10_2203_dose_response_09_036_Chiang crossref_primary_10_1016_j_coph_2009_06_002 crossref_primary_10_1093_carcin_bgp205 crossref_primary_10_1016_S0009_8981_03_00048_2 crossref_primary_10_1002_ijc_23689 crossref_primary_10_1038_nrurol_2010_102 crossref_primary_10_1007_s10552_005_0334_2 crossref_primary_10_1111_j_1527_3466_2005_tb00160_x crossref_primary_10_1200_JCO_2008_18_8938 crossref_primary_10_3945_jn_111_153114 crossref_primary_10_1016_j_urolonc_2023_07_009 crossref_primary_10_1038_s41430_019_0460_7 crossref_primary_10_1007_s10620_006_9489_2 crossref_primary_10_1038_sj_bjc_6601701 crossref_primary_10_1093_jnci_djh125 crossref_primary_10_1016_j_jada_2004_12_021 crossref_primary_10_1007_s13197_011_0517_7 crossref_primary_10_1186_1471_2407_3_25 crossref_primary_10_1111_j_1365_2362_2010_02373_x crossref_primary_10_4163_kjn_2010_43_3_304 crossref_primary_10_1152_japplphysiol_00421_2005 crossref_primary_10_3945_ajcn_2009_27535 crossref_primary_10_1016_j_spre_2007_10_002 crossref_primary_10_1007_s11934_005_0005_6 crossref_primary_10_1016_j_envres_2005_12_001 crossref_primary_10_1111_pbr_12362 crossref_primary_10_1016_j_bmc_2005_11_045 crossref_primary_10_2134_agronj2009_0140 crossref_primary_10_1207_S15327914nc391_9 crossref_primary_10_1093_jnci_djw153 crossref_primary_10_1016_j_jlumin_2017_02_056 crossref_primary_10_18632_oncotarget_15460 crossref_primary_10_1007_s10552_007_9072_y crossref_primary_10_1017_S0007114507727447 crossref_primary_10_1080_10408398_2020_1711704 crossref_primary_10_1073_pnas_0408340102 crossref_primary_10_1093_jnci_djh137 crossref_primary_10_3802_jgo_2012_23_3_190 crossref_primary_10_1002_ijc_10866 crossref_primary_10_1002_pros_20915 crossref_primary_10_1016_j_urology_2004_04_012 crossref_primary_10_1093_jnci_djt456 crossref_primary_10_3945_ajcn_2008_26205 crossref_primary_10_1007_s11746_013_2330_0 crossref_primary_10_1080_02841860902946546 crossref_primary_10_1097_00005392_200112000_00006 crossref_primary_10_1021_jf0623844 crossref_primary_10_1079_PNS2005467 crossref_primary_10_1158_1535_7163_MCT_07_0172 crossref_primary_10_1080_10590501_2012_731957 crossref_primary_10_1002_mnfr_200800113 crossref_primary_10_1016_S1040_8428_03_00042_8 crossref_primary_10_1038_srep19213 crossref_primary_10_1093_jnci_djh147 crossref_primary_10_1207_S15327914NC421_14 crossref_primary_10_1158_1940_6207_CAPR_12_0045 crossref_primary_10_1016_j_jplph_2005_04_017 crossref_primary_10_1002_ijc_21058 crossref_primary_10_1158_1940_6207_CAPR_09_0152 crossref_primary_10_1007_s11356_015_4555_y crossref_primary_10_1515_CCLM_2003_153 crossref_primary_10_1016_j_clinbiochem_2008_02_003 crossref_primary_10_3389_fsufs_2020_555426 crossref_primary_10_1158_1055_9965_EPI_16_0104 crossref_primary_10_1002_pros_22717 crossref_primary_10_1093_jnci_djj050 crossref_primary_10_1016_j_bbrc_2004_01_100 crossref_primary_10_1097_MD_0000000000005944 crossref_primary_10_1186_1471_2407_10_418 crossref_primary_10_1586_14737140_8_1_43 crossref_primary_10_1007_s00345_011_0810_0 crossref_primary_10_1080_13685530412331284722 crossref_primary_10_1016_j_ejca_2006_02_027 crossref_primary_10_1186_1472_6769_7_2 crossref_primary_10_1097_MOU_0b013e3280eb110f crossref_primary_10_1097_00001622_200205000_00006 crossref_primary_10_1207_S15327914NC4601_01 crossref_primary_10_1200_JCO_2005_02_5460 crossref_primary_10_1016_j_nutres_2021_07_004 crossref_primary_10_1002_jsfa_3039 crossref_primary_10_1158_0008_5472_CAN_08_1827 crossref_primary_10_1002_ijc_24106 crossref_primary_10_1016_j_abb_2006_02_002 crossref_primary_10_1016_j_juro_2009_07_039 crossref_primary_10_1049_nbt2_12126 crossref_primary_10_3945_jn_111_141713 crossref_primary_10_3390_ijms24119240 crossref_primary_10_1158_1055_9965_EPI_17_1177 crossref_primary_10_1080_21691401_2017_1347941 crossref_primary_10_1007_s11745_002_0943_x crossref_primary_10_1016_j_jmhg_2005_06_005 crossref_primary_10_1080_10715760100301411 crossref_primary_10_1289_EHP11391 crossref_primary_10_1080_10408398_2011_638424 crossref_primary_10_1016_j_msec_2016_05_004 crossref_primary_10_1016_S0278_6915_02_00331_9 crossref_primary_10_1016_j_currproblcancer_2004_05_002 crossref_primary_10_1207_S15327914NC4402_08 crossref_primary_10_1002_pros_23160 crossref_primary_10_1038_sj_pcan_4500825 crossref_primary_10_1089_ars_2016_6633 crossref_primary_10_1080_01635580802404162 crossref_primary_10_1016_S0891_5849_01_00618_9 crossref_primary_10_3390_curroncol31090405 crossref_primary_10_2903_j_efsa_2023_7704 crossref_primary_10_1080_10408390802304222 crossref_primary_10_1002_pros_20329 crossref_primary_10_1079_BJN20041251 crossref_primary_10_1158_1078_0432_CCR_05_0937 crossref_primary_10_3390_cancers15030979 crossref_primary_10_1002_14651858_CD005195_pub3 crossref_primary_10_1002_14651858_CD005195_pub4 crossref_primary_10_1007_s10552_006_0057_z crossref_primary_10_1200_JCO_2005_03_1492 crossref_primary_10_1016_j_jpba_2016_03_021 crossref_primary_10_1016_j_nutres_2005_09_019 crossref_primary_10_1093_jnci_dji045 crossref_primary_10_1096_fj_02_0877com crossref_primary_10_1093_ajcn_74_6_714 crossref_primary_10_1007_s00394_008_2005_z crossref_primary_10_1097_00005392_200207000_00034 crossref_primary_10_1016_j_nutres_2011_03_005 crossref_primary_10_1158_1940_6207_CAPR_14_0058 crossref_primary_10_2174_1381612825666190123112647 crossref_primary_10_1016_j_urology_2003_09_019 crossref_primary_10_31665_JFB_2019_7192 crossref_primary_10_1093_jnci_dju005 crossref_primary_10_3148_66_2_2005_98 crossref_primary_10_1016_j_bbrc_2006_05_147 crossref_primary_10_1080_13685538_2018_1430129 crossref_primary_10_1002_pros_21162 crossref_primary_10_1093_jn_137_8_1974 crossref_primary_10_5483_BMBRep_2003_36_2_190 crossref_primary_10_1039_D2NJ04187A crossref_primary_10_1200_JCO_2003_08_083 crossref_primary_10_1007_s10552_006_0064_0 crossref_primary_10_1046_j_1464_410X_2003_04167_x crossref_primary_10_3390_md9112304 crossref_primary_10_1186_1475_2891_3_19 crossref_primary_10_1002_jsfa_2943 crossref_primary_10_1007_s12094_024_03692_1 crossref_primary_10_1186_1471_2407_6_13 crossref_primary_10_1080_01635581_2019_1653472 crossref_primary_10_34172_jhp_2020_15 crossref_primary_10_3389_fonc_2020_552907 crossref_primary_10_1007_s11918_009_0008_8 crossref_primary_10_1139_G10_021 crossref_primary_10_1016_j_mrfmmm_2005_04_021 crossref_primary_10_1016_S0022_5347_05_64850_1 crossref_primary_10_1016_j_freeradbiomed_2021_12_012 crossref_primary_10_1093_jnci_djn512 crossref_primary_10_1016_j_mrfmmm_2004_02_019 crossref_primary_10_1016_j_clindermatol_2010_03_026 crossref_primary_10_1007_s11912_004_0055_9 crossref_primary_10_1096_fj_02_0362fje crossref_primary_10_1007_s10552_009_9304_4 crossref_primary_10_3109_07357907_2013_800095 crossref_primary_10_1177_1534735404270578 crossref_primary_10_1093_ajcn_85_1_209 crossref_primary_10_1158_1055_9965_EPI_10_0364 crossref_primary_10_1158_1535_7163_MCT_05_0389 crossref_primary_10_3961_jpmph_2009_42_1_67 crossref_primary_10_1080_01635580902825654 crossref_primary_10_1093_jn_133_10_3137 crossref_primary_10_7314_APJCP_2014_15_5_1897 crossref_primary_10_1371_journal_pone_0040204 crossref_primary_10_1158_1940_6207_CAPR_10_0259 crossref_primary_10_1038_sj_onc_1207716 crossref_primary_10_1023_A_1015844622285 crossref_primary_10_3389_fnut_2022_936189 crossref_primary_10_1155_2018_5703929 crossref_primary_10_1016_S0014_4800_03_00021_2 crossref_primary_10_1093_aje_kwn247 crossref_primary_10_1007_s11934_009_0029_4 crossref_primary_10_1016_S0022_5347_05_65500_0 crossref_primary_10_1016_j_canlet_2013_01_051 crossref_primary_10_1016_j_pop_2005_11_003 crossref_primary_10_1093_jnci_djt186 crossref_primary_10_3390_nu16234115 |
ContentType | Journal Article |
Copyright | 2001 INIST-CNRS Copyright Superintendent of Documents Dec 20, 2000 |
Copyright_xml | – notice: 2001 INIST-CNRS – notice: Copyright Superintendent of Documents Dec 20, 2000 |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TO 7U7 7U9 C1K H94 K9. NAPCQ 7X8 |
DOI | 10.1093/jnci/92.24.2018 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Toxicology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Nursing & Allied Health Premium |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1460-2105 |
EndPage | 2023 |
ExternalDocumentID | 66045947 11121464 908257 10_1093_jnci_92_24_2018 ark_67375_HXZ_KZSMSK6V_C |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, U.S. Gov't, P.H.S Journal Article |
GeographicLocations | United States North America America |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA94028 |
GroupedDBID | --- -E4 -~X .2P .55 .GJ .I3 .XZ .ZR 08P 0R~ 186 1TH 29L 2QL 2WC 354 3O- 4.4 482 48X 53G 5GY 5RE 5VS 5WD 70D 96U AABZA AACZT AAGKA AAHTB AAJKP AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWTL ABCQX ABDFA ABEFU ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNGD ABNHQ ABNKS ABOCM ABPEJ ABPMR ABPPZ ABPTD ABQLI ABQNK ABVGC ABXVV ABZBJ ACBMB ACGFO ACGFS ACGOD ACKOT ACNCT ACPRK ACUFI ACUKT ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADXHL ADYVW AEGPL AEJOX AEKSI AEMDU AEMQT AENZO AEPUE AETBJ AETEA AEWNT AFAZI AFCHL AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AFYAG AGINJ AGKEF AGNAY AGORE AGQPQ AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BKOMP BSCLL BTRTY BVRKM C45 CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMOBN ENERS F5P F8P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GOZPB GRPMH GX1 H5~ HAR HVGLF HW0 HZ~ IH2 IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LXL LXN LXY M-Z MHKGH ML0 MVM N9A NGC NOMLY NOYVH NTWIH NVLIB O0~ OAUYM OAWHX OBH OCB OCZFY ODMLO ODZKP OGEVE OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PB- PEELM PQQKQ Q.- Q1. Q5Y R44 RD5 RNI RNS ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCURE TEORI TJX TMA TR2 TWZ UDS UPT VH1 VVN W8F WH7 WOQ X7H X7M Y6R YAYTL YHZ YKOAZ YQT YR5 YXANX ZKX ZRR ZY1 ~91 ~H1 ~X8 AAYXX CITATION -DD 8WZ A6W AAJQQ AAKAS AAPGJ AAQQT AAWDT ABSMQ ACFRR ACPQN ACUTJ ACVCV ACZBC ADMTO ADZCM AEHUL AEKPW AFFQV AFSHK AGKRT AGMDO AHGBF AJDVS APJGH AQDSO AQKUS ATTQO AVNTJ BZKNY EIHJH FA8 H13 IQODW MBLQV NU- OBFPC O~Y QBD XJT ABQTQ ADJQC ADRIX ADZXQ CGR CUY CVF ECM EIF NPM RHF VXZ YOT 7TO 7U7 7U9 C1K H94 K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c481t-83a432c49b2d546443de61c20d8e67d8053acceaf77d9f8f695474e6fda7aa023 |
ISSN | 0027-8874 1460-2105 |
IngestDate | Fri Jul 11 00:37:34 EDT 2025 Mon Jun 30 11:02:23 EDT 2025 Wed Feb 19 02:34:38 EST 2025 Mon Jul 21 09:17:59 EDT 2025 Tue Jul 01 00:44:56 EDT 2025 Thu Apr 24 23:13:17 EDT 2025 Tue Aug 05 16:49:04 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 24 |
Keywords | Human Urinary system disease Prostate disease α-Tocopherol Case control study Malignant tumor E-Vitamins Epidemiology Micronutrient Prevention Risk factor Male genital diseases Prostate Public health |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c481t-83a432c49b2d546443de61c20d8e67d8053acceaf77d9f8f695474e6fda7aa023 |
Notes | Correspondence to: Kathy J. Helzlsouer, M.D., M.H.S., Department of Epidemiology, The Johns Hopkins University School of Hygiene and Public Health, 615 N. Wolfe St., Baltimore, MD 21205 (e-mail: Khelzlso@jhsph.edu). local:0922018 istex:CE0436C607AB60A88A69E55270C6A11222C52BE3 ark:/67375/HXZ-KZSMSK6V-C PII:1460-2105 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 11121464 |
PQID | 221023169 |
PQPubID | 41605 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_72534859 proquest_journals_221023169 pubmed_primary_11121464 pascalfrancis_primary_908257 crossref_primary_10_1093_jnci_92_24_2018 crossref_citationtrail_10_1093_jnci_92_24_2018 istex_primary_ark_67375_HXZ_KZSMSK6V_C |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2000-12-20 |
PublicationDateYYYYMMDD | 2000-12-20 |
PublicationDate_xml | – month: 12 year: 2000 text: 2000-12-20 day: 20 |
PublicationDecade | 2000 |
PublicationPlace | Cary, NC |
PublicationPlace_xml | – name: Cary, NC – name: United States – name: Oxford |
PublicationTitle | JNCI : Journal of the National Cancer Institute |
PublicationTitleAlternate | JNCI J Natl Cancer Inst |
PublicationYear | 2000 |
Publisher | Oxford University Press Oxford Publishing Limited (England) |
Publisher_xml | – name: Oxford University Press – name: Oxford Publishing Limited (England) |
References | 11121450 - J Natl Cancer Inst. 2000 Dec 20;92(24):1966-7 |
References_xml | – reference: 11121450 - J Natl Cancer Inst. 2000 Dec 20;92(24):1966-7 |
SSID | ssj0000924 |
Score | 2.1898022 |
Snippet | Background: Selenium and α-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little... Selenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However, little... BACKGROUND: Selenium and alpha-tocopherol, the major form of vitamin E in supplements, appear to have a protective effect against prostate cancer. However,... |
SourceID | proquest pubmed pascalfrancis crossref istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2018 |
SubjectTerms | Aged Antioxidants Biological and medical sciences Case-Control Studies Clinical trials Humans Incidence Logistic Models Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Odds Ratio Pathology Prostate cancer Prostatic Neoplasms - blood Prostatic Neoplasms - etiology Prostatic Neoplasms - prevention & control Risk Risk Factors Selenium - administration & dosage Selenium - blood Tumors of the urinary system Urinary tract. Prostate gland Vitamin E Vitamin E - administration & dosage Vitamin E - blood |
Title | Association Between α-Tocopherol, γ-Tocopherol, Selenium, and Subsequent Prostate Cancer |
URI | https://api.istex.fr/ark:/67375/HXZ-KZSMSK6V-C/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/11121464 https://www.proquest.com/docview/221023169 https://www.proquest.com/docview/72534859 |
Volume | 92 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgkxAvE_eFDcgDQkg0XeM4Fz9WZVNH1_KwFlV7MY7jIEaXojWV0H49x5dcWpi4vESRa6eJv-Pj4-PP5yD0OsMpBzsh84Iw4h6h2PfSKE08AlNzmPs4ldqnO55Ewxn5MA9bG-36dEmZdsXNb8-V_A-qUAa4qlOy_4Bs_VAogHvAF66AMFz_CuNW39aEK3141iuXQgcMMPmzvvCrq-0ylWWp-GqyHGvnOWgQTasuFWdLnzNSjDBh2buV_ToZnGovQsuQ1TTJyqc40E0aDkLja13cLFbLteVwNLtRw7X1WA_f1VZ1f1Gxzvqtiss833DXVr4KzfvAvbb-xTAnJiYvT6V_KW7JGSZtbdozuvkXNW9CYF0WQkFEcRcr75jV4xshtScf2cns7IxNj-fTu2gXw1pCpbl4fzpqpmuKbahu82pV_CcaHKk_OGoev2G67KpR-ENRafkKRlNu0qDcvk7R9sr0Adqz-Lh9IzUP0R1ZPEL3xpZK8Rh9bgmPa4XH3RaejrstOh23EpyOC2LjNmLjVmLjGrF5gmYnx9PB0LPpNjxBEr_0koCTAAtCU5yFBOzkIJORL3AvS2QUZwmoay6E5HkcZzRP8oiGJCYyyjMecw6231O0UywLuY9cTGFiCKnwc6hBqKRpniWwchBxILGIpYO6VU8yYWPRq5QoC2Y4EQFTXc8oZpgw1fUOels3-G7CsNxe9Y2Gpq7Hr78p9mIcsuH8go0uzsfno-gTGzjocAO7ugFVbpPYQQcVlMyO-RXDykMS-BF10Kv6V1DIapeNF3K5XrEYh4H6eAc9M_g3LwxrGzBMyPM_tj1A95vhc4h2yuu1fAHGb5m-1ML7EyrAsGE |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+alpha-tocopherol%2C+gamma-tocopherol%2C+selenium%2C+and+subsequent+prostate+cancer&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=Helzlsouer%2C+K+J&rft.au=Huang%2C+H+Y&rft.au=Alberg%2C+A+J&rft.au=Hoffman%2C+S&rft.date=2000-12-20&rft.issn=0027-8874&rft.volume=92&rft.issue=24&rft.spage=2018&rft_id=info:doi/10.1093%2Fjnci%2F92.24.2018&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8874&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8874&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8874&client=summon |